Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
RESEARCH TOOLSreports
BioMarin Pharmaceutical (BMRN) Stock Price & Analysis
1,792 Followers
BMRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$76.02 - $99.56
Previous Close$77.56
Volume3.43M
Average Volume (3M)1.62M
Market Cap
$14.73B
Enterprise Value$14.77B
Total Cash (Recent Filing)$1.05B
Total Debt (Recent Filing)$1.09B
Price to Earnings (P/E)72.6
Beta0.59
Next Earnings
Jul 30, 2024EPS Estimate
$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.07
Shares Outstanding189,879,803
10 Day Avg. Volume1,797,745
30 Day Avg. Volume1,623,072
Standard Deviation0.09
R-Squared0.04
Alpha-0.00049
Financial Highlights & Ratios
Price to Book (P/B)3.18
Price to Sales (P/S)22.70
Price to Cash Flow (P/CF)77.80
P/FCF Ratio230.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.00
Enterprise Value/Gross Profit7.76
Enterprise Value/Ebitda41.69
Forecast
1Y Price Target
$109.82Price Target Upside41.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
BioMarin Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Growth DriversManagement plans to increase Voxzogo's patient supply significantly by the end of 2024, surpassing initial projections for 2025.
Product PerformanceVoxzogo's established efficacy/safety profile is a key differentiator against competitors.
Stock RecommendationAnalyst recommends buying BMRN stock as the competition's efficacy bar appears low, suggesting potential upside post-data release.
Bears Say
CompetitionInfigratinib, given orally, could pose a substantial threat to the long-term growth of Voxzogo, a daily subcutaneous injection.
Pipeline ConcernsSeveral pipeline projects have been discontinued, which may affect long-term growth prospects.
Product PerformanceThe underperformance of Roctavian, with revenues of $0.8 million missing consensus numbers by approximately $4 million, indicates challenges in its market uptake.
---
Ownership Overview
1.26% Insiders
40.17% Mutual Funds
56.68% Other Institutional Investors
1.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $76.02 and its highest was $99.56 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
Currently, no data Available
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Jul 30, 2024 which is in 72 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Apr 24, 2024. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.312 by $0.148.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is $0.34.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 189,879,800 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $0.46 in its last earnings report, beating expectations of $0.312. Following the earnings report the stock price went down -9.901%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Among the largest hedge funds holding BioMarin Pharmaceutical’s share is PRIMECAP Management Co. It holds BioMarin Pharmaceutical’s shares valued at 2B.
---
BioMarin Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$109.82 (41.59% Upside)
$109.82 (41.59% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 90%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 26.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.93%
12-Months-Change
Fundamentals
Return on Equity
4.22%
Trailing 12-Months
Asset Growth
6.82%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
---
BMRN Company Deck
---
BMRN Earnings Call
Q1 2024
0:00 / 0:00
---
BMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BMRN Stock 12 Month Forecast
Average Price Target
$109.82
▲(41.59% Upside)
Technical Analysis
Sarepta Therapeutics
―
Sangamo Biosciences
―
Gilead Sciences
―
Vertex Pharmaceuticals
―
Best Analysts Covering BMRN
1 Year
1 Year Success Rate
12/22 ratings generated profit
1 Year Average Return
+2.90%
reiterated a buy rating 2 months ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +2.90% per trade.
---